Dr. Steven Steinhubl Joins Eko Health as Chief Medical Officer

Eko Health has appointed Steven R. Steinhubl, M.D., as chief medical officer (CMO) and member of the executive leadership team.

In his new role, Dr. Steinhubl will help drive Eko’s clinical strategy, research initiatives, and external scientific collaborations, further strengthening the evidence base and accelerating artificial intelligence (AI) adoption across health systems worldwide. His multidisciplinary background spanning engineering, physiology, and medicine positions him to bridge technology innovation with practical clinical application, executives claim.

“Steve understands both the clinical realities of cardiovascular care and the promise of new technologies to improve it,” Eko Health Co-Founder/CEO Connor Landgraf stated. “As Eko expands the global reach of AI-powered cardiac detection, his leadership will help ensure our work continues to translate into meaningful outcomes for clinicians and the patients they serve.”

Dr. Steinhubl is currently the Vincent P. Reilly Professor of Biomedical Engineering at Purdue University in the Weldon School of Biomedical Engineering and is a member of the Regenstrief Center for Healthcare Engineering in West Lafayette, Ind. A globally recognized cardiologist, clinical researcher, and digital medicine pioneer, Dr. Steinhubl has dedicated his career to advancing cardiovascular care through the integration of wearable technologies, AI, and virtual-first care models.

Dr. Steinhubl’s research focuses on personal wearable sensor technologies, artificial intelligence and machine learning in healthcare, precision communication strategies in digital health, virtual-first care delivery, and the use of digital technologies to address health inequities. Over the course of his career, he has authored peer-reviewed publications and led large-scale clinical research initiatives aimed at improving early detection and prevention of cardiovascular disease.

“As a clinician and researcher, I’ve long believed that the future of cardiovascular care lies in combining high-fidelity physiological data with intelligent analytics delivered seamlessly at the point of care,” Dr. Steinhubl said. “Eko’s platform represents a powerful step toward that future. By embedding AI into a tool clinicians already use every day, we can support earlier recognition of cardiac risk without disrupting workflow. I’m excited to help expand the scientific foundation, clinical partnerships, and real-world impact of this technology.”

Dr. Steinhubl’s appointment arrives amid accelerating clinical and commercial momentum for Eko Health. Over the past year:

• CMS finalized national payment for Eko Health’s SENSORA platform under the Outpatient Prospective Payment System (OPPS).
• Former U.S. Surgeon General Dr. Jerome Adams joined Eko Health as Distinguished Medical Advisor
• The company reported results from the independently run landmark TRICORDER study published in The Lancet.

Eko Health expanded deployment of its platform through new health system partnerships, including a recent rollout at Wayne General Hospital aimed at improving access to earlier cardiovascular screening in rural communities. 

Internationally, Eko Health launched its AI-powered stethoscope platform in the United Kingdom and expanded into Canada following Health Canada clearance of the CORE 500 Digital Stethoscope. 

Together, these milestones reflect growing global adoption of AI-assisted auscultation technologies designed to bring advanced cardiac detection into everyday clinical practice, the company claims.

Eko Health is a pioneering AI early disease detection company advancing the way healthcare professionals detect and monitor heart and lung disease with its digital stethoscopes, ECG devices, software, and AI-powered analysis. Its U.S. Food and Drug Administration-cleared platform, with more than 700,000 devices sold worldwide, helps clinicians detect earlier and manage treatment more effectively to improve patient outcomes. Eko Health is headquartered in Emeryville, Calif.